Number of Clinical Trials 2002
Explore the number of clinical trials conducted in various countries; critical for medical research and innovation.
Newer data is available: Number of Clinical Trials by country 2024 β
Where does your country rank? Pick it to see its position.
Related Health statistics
More βInteractive Map
Complete Data Rankings
Rank | Actions | ||
|---|---|---|---|
1 | United States | 606 | |
2 | Canada | 45 | |
3 | Germany | 29 | |
4 | United Kingdom | 22 | |
5 | France | 13 | |
6 | Denmark | 8 | |
7 | Netherlands | 7 | |
8 | Australia | 6 | |
9 | Brazil | 5 | |
10 | South Africa | 5 | |
11 | Switzerland | 4 | |
12 | Belgium | 4 | |
13 | Italy | 4 | |
14 | Taiwan | 3 | |
15 | China | 3 | |
16 | Finland | 3 | |
17 | India | 3 | |
18 | Israel | 3 | |
19 | New Zealand | 3 | |
20 | Poland | 3 | |
21 | Portugal | 3 | |
22 | Spain | 3 | |
23 | Sweden | 3 | |
24 | Thailand | 2 | |
25 | Bangladesh | 2 | |
26 | Guinea-Bissau | 2 | |
27 | Norway | 2 | |
28 | Tanzania | 1 | |
29 | Turkey | 1 | |
30 | Uganda | 1 | |
31 | Argentina | 1 | |
32 | Austria | 1 | |
33 | Benin | 1 | |
34 | Burkina Faso | 1 | |
35 | Gambia | 1 | |
36 | Haiti | 1 | |
37 | Hungary | 1 | |
38 | Philippines | 1 | |
39 | Russia | 1 | |
40 | Singapore | 1 |
- #1
United States
- #2
Canada
- #3
Germany
- #4
United Kingdom
- #5
France
- #6
Denmark
- #7
Netherlands
- #8
Australia
- #9
Brazil
- #10
South Africa
Analysis: These countries represent the highest values in this dataset, showcasing significant scale and impact on global statistics.
- #40
Singapore
- #39
Russia
- #38
Philippines
- #37
Hungary
- #36
Haiti
- #35
Gambia
- #34
Burkina Faso
- #33
Benin
- #32
Austria
- #31
Argentina
Context: These countries or territories have the lowest values, often due to geographic size, administrative status, or specific characteristics.
Insights by country
Argentina
In 2002, Argentina ranked #28 globally with a total of 1 clinical trial. This figure is notably lower than many of its regional peers, indicating limited participation in clinical research initiatives. Contributing factors include Argentina's complex regulatory environment and economic challenges, which may hinder investment in medical research and development.
India
In 2002, India ranked #17 globally with a total of 3 clinical trials. This figure is notably low compared to leading countries in clinical research, reflecting the challenges faced by the Indian healthcare system at the time. Factors such as limited funding for research, regulatory hurdles, and a nascent pharmaceutical industry contributed to this underdevelopment in clinical trial activities.
Uganda
In 2002, Uganda ranked #38 globally with a total of 1 clinical trial. This figure is significantly lower than many of its regional neighbors, reflecting a challenging environment for clinical research. Factors contributing to this low number include limited funding for healthcare research, a lack of infrastructure, and regulatory hurdles that hinder the establishment of clinical trials in the country.
United Kingdom
The United Kingdom ranked #4 globally with 22 clinical trials in 2002. This figure was notable as it placed the UK behind only three other countries, emphasizing its strong position in the global clinical research landscape. The UK's robust healthcare system, coupled with significant investments in medical research and a favorable regulatory environment, contributed to this high number of clinical trials, facilitating advancements in health science.
France
In 2002, France ranked #5 globally with a total of 13 clinical trials. This figure is notably higher than many neighboring countries, reflecting France's robust healthcare infrastructure and commitment to medical research. The country's strong emphasis on pharmaceutical innovation and government support for research initiatives have positioned it as a leader in clinical trial activity within Europe.
Switzerland
In 2002, Switzerland ranked #13 globally with a total of 4 clinical trials. This figure is notably lower than leading countries in clinical research, highlighting Switzerland's selective focus on high-quality rather than high-quantity trials. Switzerland's robust pharmaceutical industry and strong regulatory framework contribute to its clinical trial landscape, supported by a highly educated workforce and a commitment to innovation in healthcare.
Spain
In 2002, Spain ranked #22 globally with a total of 3 clinical trials. This number is notably lower than many of its European neighbors, reflecting a regional trend where countries like Germany and France led in clinical research activity. Contributing factors to Spain's position include its evolving healthcare system and investment in biomedical research, which were still developing at the time, impacting the number of trials initiated.
China
In 2002, China ranked #14 globally with 3 clinical trials. This figure is relatively low compared to leading countries in clinical research, reflecting a nascent stage in its biomedical research landscape. The growth of clinical trials in China has been influenced by its rapidly expanding pharmaceutical sector and increasing investment in healthcare infrastructure, alongside a large and diverse population that offers a significant participant base for trials.
Portugal
In 2002, Portugal ranked #21 globally with a total of 3 clinical trials. This figure is notably lower compared to leading countries in Europe, reflecting a more modest research investment in the healthcare sector. Contributing factors include Portugal's smaller population and limited funding for clinical research, which can hinder the scale and number of trials conducted.
Guinea-Bissau
In 2002, Guinea-Bissau ranked #26 globally with a total of 2 clinical trials. This figure is relatively low compared to the global average, indicating limited research activity in the country. Contributing factors include Guinea-Bissau's underdeveloped healthcare infrastructure and economic challenges, which hinder investment in medical research and clinical studies.
Analysis & Context
In 2002, the United States led the world in the Number of Clinical Trials conducted, with a total of 606 trials, while globally, countries reported a range from 1 to 606 trials. The data covers 40 countries, revealing an average of 20.23 trials per country and a median of 3 trials. These figures highlight significant disparities in research activity across the globe.
Concentration of Clinical Trials in Developed Nations
The predominance of clinical trials in developed countries like the United States and Canada (with 45 trials) underscores the role of economic and infrastructural capacity in driving medical research. These nations benefit from robust funding mechanisms, established research institutions, and advanced healthcare infrastructure, facilitating a higher volume of trials. The presence of pharmaceutical giants and biotech firms in these regions further supports this trend, as they often spearhead clinical research initiatives.
In Europe, countries such as Germany and the United Kingdom, with 29 and 22 trials respectively, also demonstrate strong research activity. This can be attributed to their well-developed healthcare systems and policies that encourage clinical research. Additionally, the European Union's framework for clinical trials harmonizes regulations across member states, making it easier to conduct multi-country studies.
Underrepresentation in Developing Regions
Conversely, developing countries such as Benin, Haiti, and Uganda reported only 1 trial each, highlighting a stark underrepresentation in clinical research. Factors contributing to this include limited financial resources, fewer research institutions, and less stringent regulatory frameworks. The lack of trials in these areas could also be attributed to lesser access to healthcare technology and expertise, which are crucial for conducting clinical trials.
This disparity not only affects the volume of research but also the diversity of populations studied in clinical trials. The lack of representation can lead to gaps in understanding how treatments affect different demographics, potentially skewing global healthcare outcomes.
Impact of Government Policy and Investment
Government policies and investments play a crucial role in the number of clinical trials conducted. In countries like Denmark and the Netherlands, which conducted 8 and 7 trials respectively, supportive government policies and funding for medical research have been instrumental. These nations often have dedicated government agencies that promote and facilitate clinical research, helping bridge the gap between scientific innovation and practical application.
In contrast, countries with minimal trials often lack governmental support and investment in research infrastructure. This can deter international investment and collaboration, further limiting the scope of research initiatives.
Significance of Clinical Trials in Global Health
Clinical trials are essential for advancing medical knowledge and improving global health outcomes. They are a critical component of the drug development process, ensuring the efficacy and safety of new treatments. The concentration of trials in certain regions suggests a need for increased global collaboration and investment to ensure that research benefits are equitably distributed.
Countries with higher numbers of trials, such as the United States, not only contribute to scientific advancement but also gain economic benefits from a thriving research sector. Meanwhile, countries with fewer trials could potentially benefit from increased international partnerships and technology transfer initiatives.
In conclusion, the Number of Clinical Trials in 2002 reflects broader economic, policy, and infrastructural disparities. Addressing these gaps is crucial for fostering a more inclusive and effective global health research ecosystem.
Frequently Asked Questions About Number of Clinical Trials in 2002
Which country conducted the highest number of clinical trials in 2002?
The United States conducted the highest number of clinical trials in 2002, with a total of 606 trials.
What is the average number of clinical trials conducted by countries in 2002?
The average number of clinical trials conducted by countries in 2002 was 20.23.
Which country had the lowest number of clinical trials in 2002?
Benin had the lowest number of clinical trials in 2002, with just 1 trial conducted.
What is the median number of clinical trials conducted by countries in 2002?
The median number of clinical trials conducted by countries in 2002 was 3.
How many countries conducted only 1 clinical trial in 2002?
Ten countries conducted only 1 clinical trial in 2002, including Benin, Hungary, Haiti, and others.
Which countries were in the top 3 for the number of clinical trials conducted in 2002?
The top 3 countries for the number of clinical trials conducted in 2002 were the United States with 606 trials, Canada with 45 trials, and Germany with 29 trials.
Data Source
Number of clinical trials | ClinicalTrials.gov via Our World in Data
Data produced by ClinicalTrials.gov, compiled and published by Our World in Data as "Number of clinical trials".
Visit Data SourceCite this page
Geo Factbook. (n.d.). Number of Clinical Trials by Country, 2002. Retrieved November 16, 2026, from https://geofactbook.com/fact/number-of-clinical-trials/2002
The figures on this page come from Number of clinical trials | ClinicalTrials.gov via Our World in Data. For academic work, cite the original source as well.
βΊEmbed this ranking on your site
Free to embed with attribution. Shows the top 10 countries and links back to the full ranking.